Form 4 for SABS SAB Biotherapeutics, Inc.
Accepted 2022-05-23 00:00:00 ET · period of report 2022-05-20 · accession 0001209191-22-031401 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-23 | 2022-05-20 | SABS | Spragens Jeffrey G | Dir | J - Other | $0.00 | +299.0K | 312.0K | +2,300% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-20 | J | A | 299,002 | $0.00 | 312,002 | D | — | — | (F1) The Reporting Person received 207,001 shares as part of a pro-rata distribution by Big Cypress Holdings LLC, which the Reporting Person is a limited partner of, of which shares he previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis. |